Page last updated: 2024-11-12

diosbulbin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diosbulbin B: from the rhizome of Dioscorea bulbifera; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
DioscoreagenusA plant genus best known for edible underground tubers. Yam may also refer to a moist variety of sweet potato, IPOMOEA BATATAS.[MeSH]DioscoreaceaeThe yam plant family, of the order Liliales, has thick roots or tubers and net-veined, heart-shaped leaves that sometimes are lobed.[MeSH]

Cross-References

ID SourceID
PubMed CID9974762
CHEBI ID175358
MeSH IDM0570137

Synonyms (14)

Synonym
CHEBI:175358
(1s,3r,5s,6r,8r,11r,12s,13s)-3-(uran-3-yl)-5-methyl-2,9,14-trioxapentacyclo[11.2.1.18,11.01,5.06,12]heptadecane-10,15-dione
diosbulbin b
20086-06-0
S9422
AC-34284
diosbulbin-b
mfcd16660673
AKOS030632866
diosbulbinb
BS-15889
(1s,3r,5s,6r,8r,11r,12s,13s)-3-(furan-3-yl)-5-methyl-2,9,14-trioxapentacyclo[11.2.1.18,11.01,5.06,12]heptadecane-10,15-dione
(2r,3as,6s,6as,7r,10r,11ar,11bs)-2-(furan-3-yl)-11b-methyloctahydro-4h-3a,6:7,10-dimethanofuro[2,3-c]oxepino[4,5-e]oxepine-4,8(6h)-dione
CCG-267968

Research Excerpts

Overview

Diosbulbin B (DIOB) is an effective component of air potato yam with antitumor and anti-inflammatory activities. It is the main toxic component leading to hepatotoxicity.

ExcerptReferenceRelevance
"Diosbulbin B (DIOB) is an effective component of air potato yam with antitumor and anti-inflammatory activities, and it is the main toxic component leading to hepatotoxicity. "( Systems Toxicology Approaches Reveal the Mechanisms of Hepatotoxicity Induced by Diosbulbin B in Male Mice.
Ji, H; Li, H; Li, W; Ren, J; Shen, G; Song, N; Xu, B; Zhang, L, 2020
)
2.23

Effects

ExcerptReferenceRelevance
"Diosbulbin B (DIOB) has been reported to cause serious liver injury. "( Ferulic acid prevents Diosbulbin B-induced liver injury by inhibiting covalent modifications on proteins.
Chen, H; Jiang, Q; Li, M; Liu, C; Wang, J; Wang, Q; Wang, Z; Zhang, Y; Zhuo, Y, 2023
)
2.67

Toxicity

Diosbulbin B (DIOB) is an effective component of air potato yam with antitumor and anti-inflammatory activities. It is the main toxic component leading to hepatotoxicity.

ExcerptReferenceRelevance
" Based on the analysis using principle components analysis (PCA), toxic groups could be distinguished from their control groups, which suggested that the variance of the contents of bile acids could evaluate hepatotoxicity caused by ET and DB."( [Evaluation on hepatotoxicity caused by Dioscorea bulbifera based on analysis of bile acids].
Chen, CC; Hu, ZB; Ji, LL; Wang, JM; Wang, ZT; Xu, Y; Yang, L, 2011
)
0.37
"As a candidate antitumor agent, diosbulbin B (DB) can induce serious liver toxicity and other adverse reactions."( Metabolic-induced cytotoxicity of diosbulbin B in CYP3A4-expressing cells.
Hu, ZH; Ji, LL; Jiang, JZ; Mao, YC; Wang, CH; Wang, ZT; Yang, BH; Yang, L, 2017
)
1.02
"Diosbulbin B (DIOB) is an effective component of air potato yam with antitumor and anti-inflammatory activities, and it is the main toxic component leading to hepatotoxicity."( Systems Toxicology Approaches Reveal the Mechanisms of Hepatotoxicity Induced by Diosbulbin B in Male Mice.
Ji, H; Li, H; Li, W; Ren, J; Shen, G; Song, N; Xu, B; Zhang, L, 2020
)
2.23
" However, the hepatotoxicity of DBL limits its wide safe use."( Diosbulbin B: An important component responsible for hepatotoxicity and protein covalent binding induced by Dioscorea bulbifera L.
Hu, Z; Li, K; Li, W; Liu, Y; Pan, J; Peng, Y; Tan, R; Wang, Y; Zhang, S; Zheng, J; Zhou, M; Zou, Y, 2022
)
2.16
"The present study aimed to define the association of DSB content in DBL with the severity of DBL hepatotoxicity to ensure the safe use of the herbal medicine in clinical practice and to determine the role of DSB in DBL-induced liver injury."( Diosbulbin B: An important component responsible for hepatotoxicity and protein covalent binding induced by Dioscorea bulbifera L.
Hu, Z; Li, K; Li, W; Liu, Y; Pan, J; Peng, Y; Tan, R; Wang, Y; Zhang, S; Zheng, J; Zhou, M; Zou, Y, 2022
)
2.16

Pharmacokinetics

ExcerptReferenceRelevance
" The fully validated method was applied to a pharmacokinetic and urine excretion study for the first time."( Determination of diosbulbin B in rat plasma and urine by LC-MS/MS and its application in pharmacokinetic and urinary excretion studies.
Chen, B; Gan, L; Li, Y; Qiao, J; Tian, Y, 2013
)
0.73
"To study the pharmacokinetic properties and excretion of DB in rats by a sensitive UPLC-MS/MS method."( Gender-related pharmacokinetics and absolute bioavailability of diosbulbin B in rats determined by ultra-performance liquid chromatography-tandem mass spectrometry.
Chen, K; Liu, W; Ma, Y; Wang, C; Wang, X; Wang, Z; Yang, B; Zhang, Q, 2013
)
0.63
" Main pharmacokinetic parameters including area under the plasma concentration-time curve (AUC), elimination half time (t1/2), mean residence time (MRT), apparent volume of distribution (Vd) and clearance rate (CL) were estimated using a non-compartmental pharmacokinetics data analysis software."( Gender-related pharmacokinetics and absolute bioavailability of diosbulbin B in rats determined by ultra-performance liquid chromatography-tandem mass spectrometry.
Chen, K; Liu, W; Ma, Y; Wang, C; Wang, X; Wang, Z; Yang, B; Zhang, Q, 2013
)
0.63
"A simple and sensitive UPLC-MS/MS method was developed to determine the pharmacokinetic profiles of DB in rats, as well as the excretion in rat urine."( Gender-related pharmacokinetics and absolute bioavailability of diosbulbin B in rats determined by ultra-performance liquid chromatography-tandem mass spectrometry.
Chen, K; Liu, W; Ma, Y; Wang, C; Wang, X; Wang, Z; Yang, B; Zhang, Q, 2013
)
0.63

Bioavailability

ExcerptReferenceRelevance
" Absolute bioavailability and gender-related pharmacokinetic properties, as well as excretion fractions of DB in urine and feces after oral and intravenous administrations would be addressed for the first time."( Gender-related pharmacokinetics and absolute bioavailability of diosbulbin B in rats determined by ultra-performance liquid chromatography-tandem mass spectrometry.
Chen, K; Liu, W; Ma, Y; Wang, C; Wang, X; Wang, Z; Yang, B; Zhang, Q, 2013
)
0.63
" Gender exerted a significant influence on the pharmacokinetics and bioavailability of DB in rats."( Gender-related pharmacokinetics and absolute bioavailability of diosbulbin B in rats determined by ultra-performance liquid chromatography-tandem mass spectrometry.
Chen, K; Liu, W; Ma, Y; Wang, C; Wang, X; Wang, Z; Yang, B; Zhang, Q, 2013
)
0.63

Dosage Studied

ExcerptRelevanceReference
" Further results showed that compound diosbulbin B demonstrated anti-tumor effects in the dose-dependent manner at the dosage of 2 to 16 mg/kg without significant toxicity in vivo."( Antitumor activity of Dioscorea bulbifera L. rhizome in vivo.
Branford-White, CJ; Ji, LL; Liu, H; Shen, KK; Wang, JM; Wang, ZT; Wang, ZY, 2012
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphthofuran
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's26 (81.25)24.3611
2020's6 (18.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.68 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]